Davey MG, Ryan EJ, Boland MR, et al. - By conducting a systematic review and meta-analysis, researchers sought to compare responses to neoadjuvant endocrine therapy (NET) among patients suffering from estrogen receptor positive (ER+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer after substratification via Recurrence Score (RS) testing [OncotypeDX RS represents a multigene panel employed to assist treatment decision making in early-stage, ER+/HER2- breast cancer]. Studies that assessed pathological complete response, partial response, as well as successful conversion to breast conservation surgery rates post-NET guided by RS were selected. This analysis involved eight prospective studies comprising 691 patients. As per estimates generated in this study, there was four times more likelihood to respond to NET in patients with low-intermediate RS on core biopsy when compared with those with high-risk RS. Conducting RS testing on diagnostic biopsy may be beneficial in guiding NET prescription.